5 results about "Biomodulators" patented technology

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.

A sensor array for monitoring and customizing photobiologically modulated doses is disclosed. The sensor array includes a temperature sensor for monitoring the surface temperature at the target treatment site when photons are emitted from a photobiologically modulated device onto the target treatment site.

The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator the of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.

To provide steroid derivative modulators, a method for preparing the same, and uses thereof.SOLUTION: The invention relates to steroid derivative modulators, a method for preparing the same, and uses thereof. In particular, the invention relates to a compound represented by the general formula (I), a method for preparing the same, a pharmaceutical composition containing the compound, and applications thereof as a GABAA receptor modulator in treating depression, convulsion, Parkinson's disease, and nervous system diseases, where the substituents in the general formula (I) are the same as defined in the specification.SELECTED DRAWING: None

The invention discloses a nano-carrier-based plant-derived biological regulator delivery method, and particularly relates to the technical field of nano-material application, and the method comprises the following steps: constructing a locked risk map based on soil mineral distribution, carrying out responsive structure modification on a high-adsorption area nano-carrier, and regulating and controlling the release rhythm of the nano-carrier; in combination with release history and soil microenvironment characteristics, the nano-carrier structure is subjected to multi-level regulation and control, and a release path is dynamically adjusted; in the application process, rhizosphere distribution and plant response data are collected through the nanoprobe, a next-round delivery strategy is modeled and optimized, and closed-loop accurate delivery of the plant-source biological regulator is achieved; according to the method, high-adsorption area identification before application is achieved through soil mineral map construction, the release rhythm is controlled by adopting a response type nano-carrier structure, the release path and dosage are dynamically adjusted in combination with data collected by a rhizosphere probe, multi-period, regionalized and closed-loop regulator delivery is achieved, and application accuracy and environmental adaptability are improved.